Receptor for advanced glycation end products (RAGE): A novel therapeutic target for diabetic vascular complication

Current Pharmaceutical Design

Volumn 14, Issue 5, 2008, Pages 487-495

  Yamagishi, Sho Ichi ^a   Nakamura, Kazuo ^a   Matsui, Takanori ^a   Noda, Yoshihiro ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; Diabetic vascular complication; Oxidative stress; RAGE

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADVANCED GLYCATION END PRODUCT RECEPTOR; BERAPROST; CANDESARTAN; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEDIPINE; OLMESARTAN; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTERY INJURY; ATHEROSCLEROSIS; BLINDNESS; CELL PROLIFERATION; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; GLOMERULOSCLEROSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOW DRUG DOSE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CALCIUM CHANNEL BLOCKERS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DIPHOSPHONATES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECEPTORS, IMMUNOLOGIC;

EID: 42049109529     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208783597416     Document Type: Review

References (116)

1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42.
2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
3. Yamagishi S, Imaizumi T. Diabetic vascular complications: patho-physiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-99.
4. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381-9.
5. Writing Team For The Diabetes Control And Complications Trial/ Epidemiology Of Diabetes Interventions And Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-67.
6. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
7. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.
8. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266: 11654-60.
9. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991; 266: 11649-53.
10. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 63-79.
11. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmcol Res 2003; 23: 129-34.
12. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern. Med 2002; 251: 87-101.
13. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37: 586-600.
14. Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: Insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 2002; 4: 228-37.
15. Schmidt AM, Stem D. Atherosclerosis and diabetes: The RAGE connection. Curr Atheroscler Rep 2000; 2: 430-6.
16. Stitt AW, Bucala R, Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann N Y Acad Sci 1997; 811: 115-27.
17. Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res 2004; 1: 39-46.
18. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995; 70: 10017-26.
19. Bucala, Cerami A. Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34.
20. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-51.
21. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 1995; 46: 223-34.
22. Takeuchi M, Yamagishi S. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med Hypotheses 2004; 63: 453-5.
23. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
24. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A, et al. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995; 270: 10828-32.
25. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-4.
26. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-403.
27. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995; 1: 447-56.
28. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997; 96: 2262-71.
29. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 275: 25781-90.
30. Yamagishi S, Fujimori H, Yonekura H, Tanaka N, Yamamoto H. Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem Biophys Res Commun 1999; 258: 353-7.
31. Shaw SS, Schmidt AM, Banes AK, Wang X, Stern DM, Marrero MB. S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes 2003; 52: 2381-8.
32. Sakaguchi T, Yan SF, Yan SD, Belov D; Rong LL, Sousa M, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111: 959-72.
33. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-37.
34. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 43: 1649-56.
35. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997; 99: 1272-80.
36. Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999; 10: 822-32.
37. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation 2003; 108: 1070-7.
38. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108: 261-8.
39. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 1998; 4: 1025-31.
40. Bucciarelli L, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-35.
41. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 2916-24.
42. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 2007; 48: 858-65.
43. L'Esperance FA, James WA, Judson PH. In: Lifkin H, Porte D Ed, The eye and diabetes mellitus. Ellenberg and Rifkin's Diabetes Mellitus, Theory and Practice. New York, Elsevier 1990; 661-83.
44. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmo 1961; 66: 366-78.
45. Mandarino LJ. Current hypotheses for the biochemical basis of diabetic retinopathy. Diabetes Care 1992; 15: 1892-901.
46. Frank RN. On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology 1991; 98: 586-93.
47. Sims DE. Recent advances in pericyte biology-implications for health and disease. Can J Cardiol 1991; 7: 431-43.
48. Yamagishi S, Kobayashi K, Yamamoto H. Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells. Biochem Biophys Res Common 1993; 190: 418-25.
49. Yamagishi S, Hsu CC, Kobayashi K, Yamamoto H. Endothelin 1 mediates endothelial cell-dependent proliferation of vascular pericytes. Biochem Biophys Res Commun 1993; 191: 840-6.
50. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA. An active form of transforming growth factor-P was produced by co-cultures of ECs and pericytes. Proc Natl Acad Sci USA 1989; 86: 4544-9.
51. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002; 51: 3107-12.
52. Anderson S. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int Suppl 1997; 63: S107-10.
53. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Inoue H, Takeuchi M, et al. Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs Exp Clin Res 2003; 29: 75-80.
54. Amano S, Yamagishi S, Inagaki Y, Okamoto T. Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation. Int J Tissue React 2003; 25: 51-5.
55. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50.
56. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
57. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 1995; 27: 48-52.
58. Friedman EA. In: Lifkin H, Porte D Ed, Diabetic renal disease. Ellenberg and Rifkin's Diabetes Mellitus, Theory and Practice, New York, Elsevier 1990; 684-709.
59. Ismail N, Cornell S. In: Ritz E, Rychlik I Ed, Epidemiology of type 2 diabetes and diabetic nephropathy in different ethnicities. Nephropathy in type 2 diabetes, New York, Oxford University Press 1999; 12-24.
60. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-46.
61. Taft J, Nolan CJ, Yeung SP. Hewitson TD, Martin FI, Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046-51.
62. Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 1993; 43: 661-7.
63. Ziyadeh FN, Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int 1991; 39: 404-75.
64. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-61.
65. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H. Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 2005; 579: 4265-70.
66. Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, Matsui T, Jinnouchi Y, et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005; 70: 137-4
67. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-γ (PPAR-γ)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7: 463-9.
68. Mamputu JC, Renier G. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: Inhibitory effect of antioxidants. J Leukoc Biol 2004; 75: 1062-9.
69. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999; 96: 10836-41.
70. Matsumoto Y, Takahashi M, Ogata M. Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. Jpn J Ophthalmol 2002; 46: 406-12.
71. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003; 52: 2586-93.
72. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80.
73. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NB. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
74. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 3090-4.
75. Yamagishi S, Nakamura K, Takenaka K, Matsui T, Inoue H. Pleiotropic effects of nifedipine on atherosclerosis. Curr Pharm Des 2006; 12: 1543-7.
76. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-9.
77. Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, et al. Telmisartan, an angiotensin II type 1 receptor antagonist, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-γ activation. J Int Med Res 2007; 35: 482-9.
78. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia. 2006; 49: 3094-9.
79. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett 2006; 580: 2788-96.
80. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: A causal factor. Cardiovasc Res 2006; 71: 30-9.
81. Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: Metabolic and antiatherogenic consequences. Diabetes Care 2005; 28: 757-8.
82. Miyata T, van Y persele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-87.
83. Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, et al. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res 2007; (in press).
84. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274-82.
85. Sebekova K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, Heidland A. Advanced glycation end-product levels in subtotally nephrectomized rats: beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab 1999; 25: 380-3.
86. Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-20.
87. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16: 2976-84.
88. Yamagishi S, Takeuchi M, Inoue H. Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats. Drugs Exp Clin Res 2005; 31: 45-51.
89. Sebekova K, Gazdikova K, Syrova D, Blazicek P, Schinzel R, Heidland A, et al. Effects of ramipril in nondiabetic nephropathy: Improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 2003; 17: 265-70.
90. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan. Diabetes Res Clin Prac 2006; 74: 201-3.
91. Yamagishi S, Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res 2004; 30: 169-75.
92. Matsui T, Yamagishi S, Nakamura K, Inoue H, Takeuchi M. Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells. J Int Med Res 2007; 35: 107-12.
93. Yamagishi S, Inagaki Y, Kikuchi S. Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exp Clin Res 2003; 29: 147-52.
94. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 2505-12.
95. 2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol Med 2002; 8: 546-50.
96. Ottonello L, Morone MP, Dapino P, Dallegri F. Tumor necrosis factor-alpha-induced oxidative burst in neutrophils adherent to fibronectin: Effects of cyclic AMP-elevating agents. Br J Haematol 1995; 91: 566-70.
97. Boeri D, Maiello M, Lorenzi M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 2001; 50: 1432-9.
98. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitoi-1 in human microvascular endothelial cells. Diabetologia 1998; 41: 1435-41.
99. Yamagishi S, Yamamoto Y, Harada S, Hsu CC, Yamamoto H. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothehal cells through interactions with their receptors. FEBS Lett 1996; 384: 103-6.
100. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006; 3: 73-7.
101. Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima T, Yamashita J, et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995; 270: 28316-24.
102. Yamagishi S, Kawakami T, Fujimori H, Yonekura H, Tanaka N, Yamamoto Y, et al. Insulin stimulates the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. Microvasc Res 1999; 57: 329-39.
103. Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S, Tanaka N, et al. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 1999; 79: 501-9.
104. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002; 277: 20309-15.
105. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16: 1928-30.
106. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Takeuchi M, Kikuchi S, et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun 2002; 297: 419-24.
107. Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006; 281: 220213-20.
108. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, et al. Atorvastatin inhibits advanced glycation end products (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing reactive oxygen species generation. Vase Dis Prevent 2007; 4: 213-6.
109. Yamagishi S, Matsui T, Nakamura K, Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React 2005; 27: 189-95.
110. Yamagishi S, Nakamura K, Matsui T, Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. Med Hypotheses 2006; 66: 273-5.
111. Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and im proves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 2004; 165: 1865-74.
112. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
113. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPS 33). Lancet 1998; 352: 837-53.
114. Stenina OI. Vascular complications of diabetes. Curr Pharm Des 2005; 11(18): 2277-8.
115. Yamagishi S, Imaizumi T. Diabetic vascular compfications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11 (18): 2279-99.
116. Yamagishi S, Matsui T, Nakamura K. Atorvastatin and diabetic vascular complications. Curr Pharm Des 2006; 12(12): 1549-54.